Shire and Parion Sciences to collaborate on P-321 for ophthalmic indications

by The Medical News • 2017/05/03 • 0 Comments

Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.

← Research reveals 9.8 million Brits risk losing their sight after shunning eye tests

Invivoscribe receives FDA approval for the LeukoStrat CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt →

Post navigation